Results 21 to 30 of about 4,879 (225)
CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 2, Page 261-273, February 2023., 2023 Abstract Physiologically based pharmacokinetic models, populated with drug‐metabolizing enzyme and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment (HI) on the pharmacokinetics (PK) of drugs. To increase confidence in the predictive power of such models, they must be validated by comparing the predicted and observed
Mayur K. Ladumor +7 more
wiley +1 more source
Disease Markers, Volume 2023, Issue 1, 2023., 2023 Objective. Patients with cirrhosis and splenomegaly often have coagulation dysfunction which affects treatment and prognosis. This study explores the status, grading, and treatment strategies of coagulation dysfunction in patients with liver cirrhosis and splenomegaly. Methods.
Yunfu Lv +7 more
wiley +1 more source
Hypothermia for Portacaval Shunts
Annals of Surgery, 1959 Ralph D. Junker +3 more
openaire +5 more sources
CNS Neuroscience &Therapeutics, Volume 28, Issue 11, Page 1861-1874, November 2022., 2022 Immunotherapy has emerged as a promising treatment for GBM patients. The impact of several molecular and clinical variables on survival outcomes of GBM patients treated with immunotherapy has been comprehensively assessed in this systematic review and meta‐analysis.
Gergana Mincheva +9 more
wiley +1 more source
Portal Hypertension &Cirrhosis, Volume 1, Issue 2, Page 133-144, September 2022., 2022 Prognostic tools for survival prediction and risk stratification after transjugular intrahepatic portosystemic shunt placement. Abstract Patient prognosis after transjugular intrahepatic portosystemic shunt (TIPS) placement is relatively poor and highly heterogeneous; therefore, a prognostic scoring system is essential for survival prediction and risk ...
Chongtu Yang, Bin Xiong
wiley +1 more source
Hepatology Communications, Volume 6, Issue 7, Page 1803-1812, July 2022., 2022 Patients with chronic, obliterative portal vein thrombosis may be converted to liver transplantation candidacy following portal vein recanalization‐transjugular intrahepatic portosystemic shunt (PVR‐TIPS). Long‐term survival outcomes of patients with chronic, obliterative portal vein thrombosis who undergo transplantation following PVR‐TIPS are similar
Abhinav Talwar +15 more
wiley +1 more source
Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis. [PDF]
Surgery, 2015 Orloff MJ +7 more
europepmc +3 more sources
The Journal of Clinical Pharmacology, Volume 62, Issue 6, Page 812-822, June 2022., 2022 Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study investigated the impact of hepatic impairment (HI) on acalabrutinib pharmacokinetics (PK) and safety at a single 50‐mg
Yan Xu +13 more
wiley +1 more source
Easy to say, hard to do. To the anniversary of two fundamental discoveries. Part 3
Трансплантология (Москва), 2023 On the eve of the anniversaries of two historical events: the 145th anniversary of the experiments in which Eck's fistula was performed and the 55th anniversary of the successful clinical approbation of the selective distal splenorenal anastomosis, a ...
A. Yu. Anisimov
doaj +1 more source
Journal of Neuroendocrinology, Volume 34, Issue 2, February 2022., 2022 GABA is the major inhibitory moderating system in the CNS. GABA binds its receptor and allows Cl‐ ions flow through the receptor in or out of the neuron. GAMS causes an amplification of the Cl‐ flow that causes symptoms. GAMSA binds to its receptor and counteracts the GAMS amplification of GABA and by that decrease symptoms.
Torbjörn Bäckström +2 more
wiley +1 more source